@misc{rosenstock_emral_sauque-reyna_mohan_trescolí_sifri_lalic_alvarez_picard_bonnemaire_et al._2021, 
  title={Advancing Therapy in Suboptimally Controlled Basal Insulin-Treated Type 2 Diabetes: Clinical Outcomes with iGlarLixi versus Premix BIAsp 30 in the SoliMix Randomized Controlled Trial}, 
  DOI={10.2337/figshare.14754426.v1}, 
  abstractNote={<jats:p>&lt;p&gt;&lt;b&gt;Objective:
&lt;/b&gt;To directly compare the efficacy and safety of a
fixed-ratio combination, iGlarLixi, with a premix insulin analog (BIAsp 30) as
treatment advancement in type 2 diabetes suboptimally controlled on basal
insulin plus oral antihyperglycemic drugs (OADs).&lt;/p&gt;

&lt;p&gt;&lt;b&gt;Research
Design and Methods: &lt;/b&gt;SoliMix, a
26-week, open-label, multicenter study, randomized adults with suboptimally
controlled basal insulin-treated type 2 diabetes (HbA&lt;sub&gt;1c&lt;/sub&gt; ≥7.5 % and
≤10 %) to once-daily iGlarLixi or twice-daily BIAsp 30. Primary efficacy
endpoints were non-inferiority in HbA&lt;sub&gt;1c&lt;/sub&gt; reduction (margin 0.3 %) or
superiority in bodyweight change for iGlarLixi versus BIAsp 30.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;Results:
&lt;/b&gt;Both primary efficacy endpoints were met: after 26
weeks, baseline HbA&lt;sub&gt;1c&lt;/sub&gt; (8.6 %) was reduced by 1.3 % with iGlarLixi
and 1.1 % with BIAsp 30, meeting non-inferiority (least squares [LS] mean
difference [97.5% CI]: -0.2 [-0.4, -0.1] %; p&lt;0.001). iGlarLixi was also
superior to BIAsp 30 for bodyweight change (LS mean difference [95% CI] -1.9
[-2.3, -1.4] kg) and percentage of participants achieving HbA&lt;sub&gt;1c&lt;/sub&gt;
&lt;7 % without weight gain and HbA&lt;sub&gt;1c&lt;/sub&gt; &lt;7 % without weight gain
and without hypoglycemia (all p&lt;0.001). iGlarLixi was also superior versus
BIAsp 30 for HbA&lt;sub&gt;1c&lt;/sub&gt; reduction (p&lt;0.001). Incidence and rates of
ADA Level 1 and 2 hypoglycemia were lower with iGlarLixi versus BIAsp 30.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;Conclusions:
&lt;/b&gt;Once-daily iGlarLixi provided better glycemic control
with weight benefit and less hypoglycemia than twice-daily premix BIAsp 30.
iGlarLixi is a more efficacious, simpler, and well-tolerated alternative to
premix BIAsp 30 in suboptimally controlled type 2 diabetes requiring treatment
beyond basal insulin plus OAD therapy.&lt;/p&gt;

&lt;b&gt;&lt;br&gt;
&lt;/b&gt;

&lt;p&gt; &lt;/p&gt;</jats:p>}, 
  publisher={American Diabetes Association}, 
  author={Rosenstock, Julio and Emral, Rifat and Sauque-Reyna, Leobardo and Mohan, Viswanathan and Trescolí, Carlos and Sifri, Saud Al and Lalic, Nebojsa and Alvarez, Agustina and Picard, Pascaline and Bonnemaire, Mireille and et al.}, 
  year={2021}, 
  month={Jun}
  }